Abstract
The successful targeting of growth factor receptors is one of the most fruitful areas of new drug discovery and development in recent years.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Parkin DM, Bray F, Ferlay J. Global Cancer Statistics 2002. CA Cancer J Clin. 2005;55:74-108.
Jemal A, Center MM, Desantis C. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010;19:1893-1907.
Althuis MD, Dozier JD, Anderson WF. Global trends in breast cancer incidence and mortality 1973-1997. Int J Epidemiol. 2005;34:405-412.
Autier P, Boniol M, La Vecchia C. Disparities in breast cancer mortality trends between 30 European countries: retrospective trend analysis of WHO mortality database. BMJ. 2010;341:c3620.
Slamon DJ, Clark GM, Wong SG. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177-182.
Sjogren S, Inganas M, Lindgren A. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol. 1998.16:462-469.
Yarden Y, Sliwkowski M. Untangling the ErbB signaling network. Nat Rev Mol Cell Biol. 2001;2:127-137.
Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer. 2004;4:361-370.
Menard S et al. HER2 as a prognostic factor in breast cancer. Oncology. 2001;61(suppl.2):67-72.
Ross JS et al. The HER-2/neu oncogene in breast cancer prognostic factor, predictive factor and target for therapy. Stem Cells. 1998;16:413-428.
Van de Vijver MJ et al. Neu-protein overexpression in breast cancer. Association with comedotype ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med. 1988; 319:1239-1245.
Lu J et al. 14‑3‑3ζ cooperates with ErbB2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial-mesenchymal transition. Cancer Cell. 2009;16:195-207.
Lipton A, Kostler WJ, Leitzel K. Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab. Cancer. 2010;116:5168–5178.
Bargmann CI, Hung MC, Weinberg RA. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature. 1986;319(6050):226-230.
Coussens L, Yang-Feng TL, Liao YC. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science. 1985;230:1132-1139.
Brandt-Rauf PW, Monaco R, Pincus MR. Conformation of the transmembrane domain of the epidermal growth factor receptor. J Protein Chem. 1994;13:227-231.
Gullick WJ, Bottomley AC, Lofts FJ. Three dimensional structure of the transmembrane region of the proto-oncogenic and oncogenic forms of the neu protein. EMBO J. 1992;11:43-48.
Yarden Y, Pines G. The ERBB network: at last, cancer therapy meets systems biology. Nat Rev Canc. 2012;12:553-563.
Schlessinger J. Signal transduction by allosteric receptor oligomerization. Trends Biochem Sci. 1988;13:443-447.
Pinkas-Kramarski R, Soussan L, Waterman H. Diversification of Neu differentiation factor and epidermal growth factor signalling by combinatorial receptor interactions. EMBO J. 1996;15:2452-2467.
Graus-Porta D, Beerli RR, Daly JM. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. 1997;16:1647-1655.
Ahn ER, Vogel CL. Dual HER2-targeted approaches in HER2-positive breast cancer. Breast Cancer Res Treat. 2012;131:371-383.
Amit I, Wides R, Yarden Y. Evolvable signaling networks of receptor tyrosine kinases: relevance of robustness to malignancy and to cancer therapy. Mol Syst Biol. 2007;3:151.
Garrett JT, Arteaga, CL. Resistance to HER2‑directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications. Cancer Biol Ther. 2011;11:793-800.
Rexer BN, Engelman JA, Arteaga CL. Overcoming resistance to tyrosine kinase inhibitors: lessons learned from cancer cells treated with EGFR antagonists. Cell Cycle. 2009; 8:18-22.
Scaltriti M, Rojo F, Ocana A, et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti‑HER2 therapies in breast cancer. J Natl Cancer Inst. 2007;99:628-638.
Hubalek M, Brunner C, Mattha K, Marth C. Resistance to HER2-targeted therapy: mechanisms of trastuzumab resistance and possible strategies to overcome unresponsiveness to treatment. Wien Klin Wochenschr. 2010;160:506-512.
Pohlmann PR, Mayer IA, Mernaugh R. Resistance to trastuzumab in breast cancer. Clin Cancer Res. 2009;15:7479-7491.
Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ. Mechanisms of disease: understanding resistance to HER2‑targeted therapy in human breast cancer. Nature Clin Pract Oncol. 2006; 3:269-280.
Sergina NV, Rausch M, Wang D, et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature. 2007;445:437-441.
Berns K, Horlings HM, Hennessy BT, et al. A functional genetic approach identifies the PI3Â K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell. 2007;12:395-402.
Liu L et al. Novel mechanism of lapatinib resistance in HER2‑positive breast tumor cells: activation of AXL. Cancer Res. 2009;69:6871-6878.
Xia W, Bacus S, Hegde P, et al. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc Nat Acad Sci USA. 2006;103:7795-7800.
Prempree T, Wongpaksa C. Mutations of HER2 gene in HER2-positive metastatic breast cancer. J Clin Oncol. 2006;24:13118.
Modi S, Stopeck A, Linden, et al. HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin Cancer Res. 2011;17:5132-5139.
Goldblatt EM, Erickson PA, Gentry ER, Gryaznov SM, Herbert BS. Lipid-conjugated telomerase template antagonists sensitize resistant HER2-positive breast cancer cells to trastuzumab. Breast Cancer Res Treat. 2009;118:21-32.
Nahta R, O’Regan RM. Therapeutic implications of estrogen receptor signalling in HER2- positive breast cancers. Breast Cancer Res Treat. 2012;135:39-48.
Gluck S, Arteaga CL, Osborne CK. Optimizing chemotherapy-free survival for the ER/HER2- positive metastatic breast cancer patient. Clin Cancer Res. 2011;17:5559–5561.
Sabnis G, Schayowitz A, Goloubeva O, Macedo L, Brodie A. Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen. Cancer Res. 2009;69:1416-1428.
Mohd Sharial MS, Crown J, Hennessy BT. Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer. Ann Oncol. 2012;23: 3007-3016.
Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hasmann M. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res. 2009; 69:9330-9336.
Baselga J, Gelmon KA, Verma S, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol. 2010; 1;28:1138-1144.
Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13:25-32.
Baselga J, Cortes J, Kim SB, et al; for the CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366:109-119.
J Baselga, I Bradbury, H Eidtmann, et al; for the NeoALTTO Study Team, Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. The Lancet. 2012; 379: 633-640.
TT Junttila, RW Akita, K Parsons, et al. Ligand-independent HER2/HER3/PI3Â K complex is disrupted by trastuzumab and is effectively inhibited by the PI3Â K inhibitor GDC-0941. Cancer Cell. 2009;15:429-440.
Jerusalem G, Fasolo A, Dieras V, et al. Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2- overexpressing metastatic breast cancer. Breast Cancer Res Treat. 2011;125:447-455.
O’Regan R, Ozguroglu M, Andre F, et al. Phase III, randomized, double-blind, placebocontrolled multicenter trial of daily everolimus plus weekly trastuzumab and vinorelbine in trastuzumab-resistant, advanced breast cancer (BOLERO-3). J Clin Oncol. 2013; 31(suppl): 505.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Healthcare
About this chapter
Cite this chapter
Fasolo, A., Zambelli, S., Gianni, L. (2013). Introduction and Background Biology. In: Handbook of HER2-targeted agents in breast cancer. Springer Healthcare, Tarporley. https://doi.org/10.1007/978-1-907673-94-8_1
Download citation
DOI: https://doi.org/10.1007/978-1-907673-94-8_1
Published:
Publisher Name: Springer Healthcare, Tarporley
Print ISBN: 978-1-907673-93-1
Online ISBN: 978-1-907673-94-8
eBook Packages: MedicineMedicine (R0)